Characterization of the anti-tumour activity against solid tumours of a new nitrosoureido sugar: Cy 233.

Abstract

The anti-tumour properties of Cy 233, a new nitrosoureido sugar, were investigated in two murine solid tumours: B16 melanoma and subcutaneously implanted colon adenocarcinoma. Injected i.v., Cy 233 exerted a strong anti-tumour effect against the established B16 melanoma: long-term survivors were recorded with all schedules of treatment. The drug was even more effective against advanced colon 38 adenocarcinoma: it produced a high percentage of total tumour regression, regardless of the route of administration (i.p., i.v., p.o.). The marked in vivo activity of Cy 233 against advanced colon 38 adenocarcinoma, which is known to be resistant to such major anti-cancer drugs as BCNU and chlorozotocin, its water solubility and its stability in aqueous media are further elements warranting toxicological and clinical studies of this agent.

• Authors: G Atassi, P Dumont, C Gosse, J P Fournier, A Gouyette, P Roger
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 25 Issue 3 Pg. 205-9 ( 1989) ISSN: 0344-5704 [Print] Germany
• PMID: 2598412 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antineoplastic Agents
• Nitrosourea Compounds
• Taurine
• 1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea
• ecomustine
• Carmustine

Topics

• Adenocarcinoma (drug therapy)
• Animals
• Antineoplastic Agents (therapeutic use)
• Carmustine (therapeutic use)
• Colonic Neoplasms (drug therapy)
• Dose-Response Relationship, Drug
• Drug Screening Assays, Antitumor
• Female
• Male
• Melanoma, Experimental (drug therapy)
• Mice
• Mice, Inbred C57BL
• Mice, Inbred DBA
• Neoplasm Transplantation
• Nitrosourea Compounds (therapeutic use)
• Taurine (analogs & derivatives, therapeutic use)
• Time Factors